Shares of AbbVie Inc. ABBV slid 1.55% to $206.27 Tuesday, on what proved to be an all-around mixed trading session for the ...

SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc ...

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Those gains over January, when the drugs fell to third and fourth on the list, came even as spending dropped for both meds: AbbVie spent $34.8 million on Rinvoq’s TV ads and $27 million on ...

Here’s how to reach us securely. The U.S. Department of Homeland Security skipped a fully competitive bidding process to give two Republican-linked firms the first part of a $200 million television ad ...

Tenpoint Therapeutics has tasked Carol Kearney with cracking a market that confounded AbbVie. As the biotech’s newly appointed chief commercial officer, Kearney will oversee preparations to ...